<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="EASL European Association for the Study of the Liver ETV" exact="entecavir" post="HBeAg hepatitis B e antigen HBsAg hepatitis HBV surface"/>
 <result pre="PWID people who inject drugs SVR sustained virologic response TAF" exact="tenofovir alafenamide" post="TDF tenofovir disoproxil fumarate Viral hepatitis continues to contribute"/>
 <result pre="of decompensation. In patients with eGFR &amp;lt; 30 mL/min/1.73 m2," exact="sofosbuvir" post="should only be used if no alternative treatment approved"/>
 <result pre="(C) John Wiley &amp;amp; Sons, Ltd, Since the approval of" exact="telaprevir" post="and boceprevir in 2011 with SVR rates of 65%"/>
 <result pre="Wiley &amp;amp; Sons, Ltd, Since the approval of telaprevir and" exact="boceprevir" post="in 2011 with SVR rates of 65% to 75%,"/>
 <result pre="high‐fold resistance variants to NS5A Severe renal impairment GT3: Add" exact="sofosbuvir" post="for PEG/RBV experienced with compensated cirrhosis Not for decompensated"/>
 <result pre="cirrhosis 24‐week duration and add RBV for decompensated cirrhosis with" exact="sofosbuvir" post="failure Following liver transplant with/without cirrhosis (compensated or decompensated)"/>
 <result pre="lung and 8 heart transplants) who received 4 weeks of" exact="sofosbuvir" post="and velpatasvir immediately after transplantation. The authors found that,"/>
 <result pre="8 heart transplants) who received 4 weeks of sofosbuvir and" exact="velpatasvir" post="immediately after transplantation. The authors found that, on follow‐up,"/>
 <result pre="with at least moderate liver necroinflammation or fibrosis. Abbreviations: ALT," exact="alanine" post="aminotransferase; CHB, chronic hepatitis B; ULN, upper limit of"/>
 <result pre="long‐term (up to 8 years) rates of HBV resistance to" exact="entecavir" post="(ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF)."/>
 <result pre="HBV resistance to entecavir (ETV), tenofovir disoproxil fumarate (TDF), and" exact="tenofovir alafenamide" post="(TAF). Thus, these three antiviral drugs have become the"/>
 <result pre="treatments Abbreviations: eGFR, estimated glomerular filtration rate; ETV, entecavir; TAF," exact="tenofovir alafenamide;" post="TDF, tenofovir disoproxil fumarate. (C) John Wiley &amp;amp; Sons,"/>
 <result pre="modification cccDNA inhibitors (e.g., lymphotoxin beta receptor agonist) Epi‐drugs Interferon" exact="alpha" post="Modification of cccDNA to pgRNA, pgRNA packaging for nuclear"/>
 <result pre="to progeny rcDNA and capsid packaging Capsid assembly modulators Interferon" exact="alpha" post="Viral replication through DNA synthesis Nucleoside analogs Capsid incorporation"/>
 <result pre="incorporation of HBsAg and secretion from hepatocytes Secretion inhibitors Interferon" exact="alpha" post="Abbreviations: ccc, covalently closed circular; DNA, deoxyribonucleic acid; HBsAg,"/>
 <result pre="populations.&quot;Liver Int2018;38:28‐33.29427485 24PoordadF, SchiffER, VierlingJM, LandisC, FontanaRJ, YangR, et al." exact="Daclatasvir" post="with sofosbuvir and ribavirin for hepatitis C virus infection"/>
 <result pre="24PoordadF, SchiffER, VierlingJM, LandisC, FontanaRJ, YangR, et al. Daclatasvir with" exact="sofosbuvir" post="and ribavirin for hepatitis C virus infection with advanced"/>
 <result pre="VierlingJM, LandisC, FontanaRJ, YangR, et al. Daclatasvir with sofosbuvir and" exact="ribavirin" post="for hepatitis C virus infection with advanced cirrhosis or"/>
 <result pre="SetoWK, LimY‐S, FungS, MarcellinP, et al. 96 weeks treatment of" exact="tenofovir alafenamide" post="vs. tenofovir disoproxil fumarate for hepatitis B virus infection."/>
</results>
